Strongbridge Biopharma plc Announces Acquisition of the U.S. and Canadian Rights to MACRILEN(TM) (macimorelin) from Aeterna Zentaris

Stock Information for Strongbridge Biopharma plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Strongbridge Biopharma plc

Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.
Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.
Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc.
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote "FOR" the Transaction With Xeris
Leading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders Vote "FOR" the Transaction With Xeris
INVESTIGATION: Halper Sadeh LLP Investigates SBBP, QTS, GRA, SWN, ONEM, IKNX; Shareholders are Encouraged to Contact the Firm
Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Strongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.